van 't Veer L J, Hermens R, van den Berg-Bakker L A, Cheng N C, Fleuren G J, Bos J L, Cleton F J, Schrier P I
Department of Clinical Oncology, University Hospital, Leiden, The Netherlands.
Oncogene. 1988 Feb;2(2):157-65.
Samples of 37 fresh human ovarian tumor biopsies were screened to detect proto-oncogene amplification and ras mutations. Three samples showed c-K-ras2 amplification; none of the other oncogenes tested revealed any gene amplification. 5-, 25-, and 120-fold amplifications were assessed by dilution experiments and soft laser densitometry. Corresponding elevated levels of c-K-ras2 mRNA and p21 ras protein were found in the three tumors. Analysis by the polymerase chain reaction method to detect point mutations of codon 12 or codon 61 of Harvey-, Kirsten-, or N-ras showed only the wildtype sequence in all specimens. No correlation was found between ras activation and degree of tumor progression or histological subtype. DNA from one of the tumors with c-K-ras2 amplification proved to have high transforming activity in the NIH 3T3 tumorigenicity assay, but the transforming gene was not c-K-ras2.
对37份新鲜人类卵巢肿瘤活检样本进行筛查,以检测原癌基因扩增和ras突变。3份样本显示c-K-ras2扩增;所检测的其他原癌基因均未显示任何基因扩增。通过稀释实验和软激光密度测定法评估了5倍、25倍和120倍的扩增。在这3个肿瘤中发现了相应升高的c-K-ras2 mRNA和p21 ras蛋白水平。通过聚合酶链反应法分析检测Harvey-、Kirsten-或N-ras的第12密码子或第61密码子的点突变,结果显示所有标本中均只有野生型序列。未发现ras激活与肿瘤进展程度或组织学亚型之间存在相关性。在NIH 3T3致瘤性试验中,来自其中一个具有c-K-ras2扩增的肿瘤的DNA被证明具有高转化活性,但转化基因不是c-K-ras2。